Single-fraction SBRT is safe and effective in treating early stage, medically inoperable NSCLC, according to a ten-year retrospective study of 229 patients, the largest single-institution report to date.
Combined SBRT + pazopanib combination is well tolerated with several benefits for select patients with pediatric sarcoma, a new study finds. Radiation oncologist Erin Murphy, MD, discusses the study.
A case report about a novel two-pronged treatment for a patient with a large hepatocellular carcinoma/cholangiocarcinoma shows the value of multidisciplinary collaboration, especially among experts in interventional radiology and radiation oncology.
Which research results from the American Society for Radiation Oncology’s 2019 annual meeting are the most interesting or clinically relevant? The staff of Cleveland Clinic Cancer Center’s Department of Radiation Oncology picks their Top 10.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Stereotactic radiosurgery, used most often for adult brain tumors, also has promising benefits for pediatric tumors. Dr. Erin Murphy shares results of her study in pilocytic astrocytoma.
A new document advises physicians on using SBRT for high-risk scenarios involving tumor size and location and previous treatments for lung cancer in medically inoperable patients.
Stereotactic body radiation therapy and proton beam therapy have theoretical advantages over the current standard of care, intensity-modulated radiation therapy. Clinical trials will be important to determine their value.
After reviewing 10 years of patient experience, researchers at Cleveland Clinic confirm that SBRT has potential to cure lung cancer with minimal side effects in early-stage patients who are medically inoperable.